Fuan Pharmaceutical Group Co (300194) — Working Capital to Net Assets Ratio
Fuan Pharmaceutical Group Co (300194) has a Working Capital to Net Assets ratio of 25.0% as of September 2025. Working capital of CN¥1.11 Billion (current assets of CN¥2.06 Billion minus current liabilities of CN¥943.69 Million) is measured against net assets of CN¥4.45 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See financial agility of Fuan Pharmaceutical Group Co to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Fuan Pharmaceutical Group Co Working Capital to Net Assets (2007–2024)
This chart shows how Fuan Pharmaceutical Group Co's Working Capital to Net Assets ratio has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the ratio stands at 25.0%, reflecting working capital of CN¥1.11 Billion against net assets of CN¥4.45 Billion CNY. See Fuan Pharmaceutical Group Co liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Fuan Pharmaceutical Group Co (2007–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Fuan Pharmaceutical Group Co from 2007 to 2024, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Fuan Pharmaceutical Group Co market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 19.1% | CN¥838.70 Million | CN¥4.40 Billion | CN¥2.07 Billion | CN¥1.23 Billion | ▼ -3.4 pp |
| 2023 | 22.4% | CN¥931.19 Million | CN¥4.15 Billion | CN¥2.13 Billion | CN¥1.20 Billion | ▲ +6.2 pp |
| 2022 | 16.2% | CN¥640.01 Million | CN¥3.95 Billion | CN¥1.93 Billion | CN¥1.29 Billion | ▼ -4.4 pp |
| 2021 | 20.6% | CN¥796.70 Million | CN¥3.87 Billion | CN¥2.09 Billion | CN¥1.29 Billion | ▲ +1.1 pp |
| 2020 | 19.5% | CN¥887.77 Million | CN¥4.56 Billion | CN¥1.95 Billion | CN¥1.06 Billion | ▼ -13.9 pp |
| 2019 | 33.4% | CN¥1.33 Billion | CN¥3.99 Billion | CN¥1.94 Billion | CN¥607.02 Million | ▲ +1.4 pp |
| 2018 | 32.0% | CN¥1.18 Billion | CN¥3.69 Billion | CN¥1.73 Billion | CN¥546.39 Million | ▲ +7.6 pp |
| 2017 | 24.4% | CN¥1.02 Billion | CN¥4.17 Billion | CN¥1.47 Billion | CN¥453.25 Million | ▲ +5.3 pp |
| 2016 | 19.2% | CN¥759.19 Million | CN¥3.96 Billion | CN¥1.11 Billion | CN¥353.11 Million | ▼ -21.0 pp |
| 2015 | 40.1% | CN¥856.78 Million | CN¥2.14 Billion | CN¥1.12 Billion | CN¥262.65 Million | ▼ -19.5 pp |
| 2014 | 59.6% | CN¥1.02 Billion | CN¥1.71 Billion | CN¥1.12 Billion | CN¥98.43 Million | ▼ -1.4 pp |
| 2013 | 61.0% | CN¥1.05 Billion | CN¥1.72 Billion | CN¥1.17 Billion | CN¥113.41 Million | ▼ -9.1 pp |
| 2012 | 70.2% | CN¥1.21 Billion | CN¥1.72 Billion | CN¥1.26 Billion | CN¥57.01 Million | ▼ -6.6 pp |
| 2011 | 76.8% | CN¥1.30 Billion | CN¥1.69 Billion | CN¥1.41 Billion | CN¥105.37 Million | ▲ +33.9 pp |
| 2010 | 42.9% | CN¥120.69 Million | CN¥281.05 Million | CN¥185.45 Million | CN¥64.76 Million | ▼ -4.4 pp |
| 2009 | 47.4% | CN¥77.35 Million | CN¥163.31 Million | CN¥151.53 Million | CN¥74.18 Million | ▲ +39.6 pp |
| 2008 | 7.8% | CN¥8.59 Million | CN¥110.76 Million | CN¥100.42 Million | CN¥91.83 Million | ▲ +442.5 pp |
| 2007 | -434.7% | CN¥-36.13 Million | CN¥8.31 Million | CN¥36.44 Million | CN¥72.58 Million | — |